Aging disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

AGING MCID: AGN016 MIFTS: 54	Aging (AGING)
Genes Tissues Related diseases Publications Pathways Drugs Expand all tables

Sources

Aliases & Classifications for Aging

MalaCards integrated aliases for Aging:

Name: Aging ⁵⁷ ⁷⁴

External Ids:

OMIM® ⁵⁷ 502000

Sources

Summaries for Aging

OMIM® : ⁵⁷ Progressive damage to mitochondrial DNA (mtDNA) during life is thought to contribute to aging processes. This notion is supported by the observation of an aging-related accumulation in human mtDNA of oxidative and alkylation derivatives of nucleotides, of small deletions and insertions, and of large deletions, although their low frequency raises questions about their functional significance (Michikawa et al., 1999). (502000) (Updated 05-Mar-2021)

MalaCards based summary : Aging is related to premature aging and werner syndrome. An important gene associated with Aging is BCYRN1 (Brain Cytoplasmic RNA 1), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs Vigabatrin and Topiramate have been mentioned in the context of this disorder. Affiliated tissues include brain, skin and bone, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Wikipedia : ⁷⁴ Senescence (/sɪˈnɛsəns/) or biological aging is the gradual deterioration of functional characteristics.... more...

Sources

Related Diseases for Aging

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1667)

#	Related Disease	Score	Top Affiliating Genes
1	premature aging	32.5	WRN SOD2 PDGFRB LMNA
2	werner syndrome	32.4	WRN PARP1 LMNA
3	hutchinson-gilford progeria syndrome	32.1	WRN SOD2 SIRT6 SIRT1 LMNA
4	progeroid syndrome	31.6	WRN LMNA
5	age-related hearing loss	31.2	SOD2 SIRT1 HIF1A
6	huntington disease	30.8	SOD2 SIRT1 REST PPARG FOXO3
7	hyperglycemia	30.8	SOD2 PPARG NAMPT HIF1A
8	non-alcoholic fatty liver disease	30.7	SOD2 SIRT3 SIRT1 PPARG NAMPT
9	osteoporosis	30.7	WRN SOD2 SIRT6 SIRT1 PPARG LMNA
10	disease of mental health	30.6	SOD2 SIRT6 SIRT3 SIRT1 REST PPARG
11	optic atrophy 1	30.4	SOD2 SIRT3 SIRT1
12	type 2 diabetes mellitus	30.2	WRN SOD2 SIRT6 SIRT1 PPARG PARP1
13	body mass index quantitative trait locus 11	30.2	SOD2 SIRT6 SIRT3 SIRT1 PPARG NAMPT
14	non-alcoholic steatohepatitis	30.2	SOD2 SIRT1 PPARG
15	diabetes mellitus	29.9	WRN SOD2 SIRT3 SIRT1 PPARG PARP1
16	pellagra	29.8	PPARG PARP1 NAMPT
17	tuberous sclerosis 1	29.6	HIF1A FOXO3 FOXO1
18	burkitt lymphoma	29.1	SIRT1 PARP1 NFKB1 FOXO1
19	medulloblastoma	29.0	WRN SIRT1 REST PDGFRB PARP1 HIF1A
20	prostate cancer	28.8	TP63 SOD2 SIRT1 PPARG PDGFRB PARP1
21	premature aging syndrome, penttinen type	11.5
22	mild cognitive impairment	11.3
23	dementia	11.3
24	alzheimer disease	11.2
25	fontaine progeroid syndrome	11.2
26	branchiooculofacial syndrome	11.2
27	short stature, hearing loss, retinitis pigmentosa, and distinctive facies	11.2
28	premature aging syndrome, okamoto type	11.2
29	cockayne syndrome	11.1
30	impotence	11.0
31	gapo syndrome	11.0
32	presbyopia	11.0
33	refractive error	11.0
34	wiedemann-rautenstrauch syndrome	10.9
35	acrogeria, gottron type	10.9
36	nestor-guillermo progeria syndrome	10.9
37	sleep disorder	10.9
38	cerebroretinal microangiopathy with calcifications and cysts 2	10.9
39	ogden syndrome	10.9
40	laminopathy with premature aging	10.9
41	cerebral amyloid angiopathy, cst3-related	10.9
42	rickets	10.9
43	ataxia-telangiectasia	10.9
44	intraocular pressure quantitative trait locus	10.9
45	mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome	10.9
46	arthritis	10.9
47	senile cataract	10.9
48	trichothiodystrophy	10.9
49	rothmund-thomson syndrome, type 2	10.8
50	longevity 1	10.8

Graphical network of the top 20 diseases related to Aging:

Sources

Symptoms & Phenotypes for Aging

Clinical features from OMIM®:

502000 (Updated 05-Mar-2021)

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

²⁶ (show all 29)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased shRNA abundance (Z-score < -2)	GR00366-A-100	10.1	NAMPT
2	Decreased shRNA abundance (Z-score < -2)	GR00366-A-104	10.1	NAMPT
3	Decreased shRNA abundance (Z-score < -2)	GR00366-A-116	10.1	NAMPT
4	Decreased shRNA abundance (Z-score < -2)	GR00366-A-120	10.1	NAMPT SIRT3
5	Decreased shRNA abundance (Z-score < -2)	GR00366-A-142	10.1	NAMPT
6	Decreased shRNA abundance (Z-score < -2)	GR00366-A-145	10.1	NAMPT SIRT3
7	Decreased shRNA abundance (Z-score < -2)	GR00366-A-153	10.1	FOXO3
8	Decreased shRNA abundance (Z-score < -2)	GR00366-A-164	10.1	NAMPT
9	Decreased shRNA abundance (Z-score < -2)	GR00366-A-166	10.1	NAMPT
10	Decreased shRNA abundance (Z-score < -2)	GR00366-A-168	10.1	HIF1A
11	Decreased shRNA abundance (Z-score < -2)	GR00366-A-169	10.1	NAMPT
12	Decreased shRNA abundance (Z-score < -2)	GR00366-A-17	10.1	NAMPT
13	Decreased shRNA abundance (Z-score < -2)	GR00366-A-181	10.1	NAMPT
14	Decreased shRNA abundance (Z-score < -2)	GR00366-A-190	10.1	PPARG
15	Decreased shRNA abundance (Z-score < -2)	GR00366-A-200	10.1	HIF1A
16	Decreased shRNA abundance (Z-score < -2)	GR00366-A-202	10.1	NAMPT
17	Decreased shRNA abundance (Z-score < -2)	GR00366-A-204	10.1	NAMPT
18	Decreased shRNA abundance (Z-score < -2)	GR00366-A-208	10.1	FOXO3
19	Decreased shRNA abundance (Z-score < -2)	GR00366-A-32	10.1	FOXO3
20	Decreased shRNA abundance (Z-score < -2)	GR00366-A-50	10.1	NAMPT
21	Decreased shRNA abundance (Z-score < -2)	GR00366-A-57	10.1	NAMPT
22	Decreased shRNA abundance (Z-score < -2)	GR00366-A-68	10.1	NAMPT
23	Decreased shRNA abundance (Z-score < -2)	GR00366-A-69	10.1	NAMPT
24	Decreased shRNA abundance (Z-score < -2)	GR00366-A-79	10.1	HIF1A
25	Decreased shRNA abundance (Z-score < -2)	GR00366-A-82	10.1	SIRT3
26	Decreased shRNA abundance (Z-score < -2)	GR00366-A-95	10.1	SIRT3
27	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.36	HIF1A NFKB1 SIRT1
28	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.36	FOXO3 HIF1A NFKB1
29	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.36	HIF1A NFKB1 PARP1 TP63 WRN

MGI Mouse Phenotypes related to Aging:

⁴⁶ (show all 26)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	cellular	MP:0005384	10.57	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
2	cardiovascular system	MP:0005385	10.52	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
3	growth/size/body region	MP:0005378	10.51	FOXO1 GDF11 HIF1A LMNA NAMPT NFKB1
4	behavior/neurological	MP:0005386	10.5	FOXO1 FOXO3 HIF1A LMNA NFKB1 PARP1
5	homeostasis/metabolism	MP:0005376	10.48	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
6	immune system	MP:0005387	10.44	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
7	integument	MP:0010771	10.43	FOXO1 FOXO3 HIF1A LMNA NAMPT NFKB1
8	mortality/aging	MP:0010768	10.43	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
9	hematopoietic system	MP:0005397	10.4	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
10	adipose tissue	MP:0005375	10.37	FOXO1 FOXO3 LMNA PDGFRB PPARG RGN
11	endocrine/exocrine gland	MP:0005379	10.36	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
12	digestive/alimentary	MP:0005381	10.34	FOXO1 FOXO3 GDF11 HIF1A LMNA NFKB1
13	craniofacial	MP:0005382	10.3	FOXO1 GDF11 HIF1A LMNA NFKB1 PDGFRB
14	embryo	MP:0005380	10.29	FOXO1 GDF11 HIF1A NAMPT PARP1 PDGFRB
15	nervous system	MP:0003631	10.25	FOXO1 FOXO3 GDF11 HIF1A LMNA NAMPT
16	liver/biliary system	MP:0005370	10.19	FOXO1 HIF1A LMNA NFKB1 PPARG RGN
17	hearing/vestibular/ear	MP:0005377	10.17	FOXO3 LMNA NFKB1 PARP1 PPARG REST
18	limbs/digits/tail	MP:0005371	10.16	FOXO1 GDF11 HIF1A LMNA PDGFRB RGN
19	muscle	MP:0005369	10.11	FOXO1 GDF11 HIF1A LMNA NFKB1 PDGFRB
20	neoplasm	MP:0002006	10.03	FOXO1 FOXO3 HIF1A PPARG SIRT1 SOD2
21	reproductive system	MP:0005389	10.03	FOXO1 FOXO3 LMNA PARP1 PDGFRB PPARG
22	normal	MP:0002873	10.02	FOXO1 HIF1A LMNA NFKB1 PDGFRB PPARG
23	renal/urinary system	MP:0005367	10.02	FOXO3 GDF11 HIF1A LMNA PARP1 PDGFRB
24	skeleton	MP:0005390	9.8	FOXO1 FOXO3 GDF11 HIF1A LMNA NFKB1
25	respiratory system	MP:0005388	9.76	FOXO3 GDF11 HIF1A LMNA NFKB1 RGN
26	vision/eye	MP:0005391	9.5	FOXO3 GDF11 HIF1A LMNA NAMPT PARP1

Sources

Drugs & Therapeutics for Aging

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1483)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Vigabatrin

Approved

Phase 4

60643-86-9, 68506-86-5

5665

Topiramate

Approved

Phase 4

97240-79-4

5284627

Everolimus

Approved

Phase 4

159351-69-6

6442177 70789204

Phenytoin

Approved, Vet_approved

Phase 4

57-41-0

1775

Valproic acid

Approved, Investigational

Phase 4

99-66-1

3121

Desogestrel

Approved

Phase 4

54024-22-5

40973

Lactulose

Approved

Phase 4

4618-18-2

11333

Basiliximab

Approved, Investigational

Phase 4

179045-86-4, 152923-56-3

Verteporfin

Approved, Investigational

Phase 4

129497-78-5

Abciximab

Approved

Phase 4

143653-53-6

Clobazam

Approved, Illicit

Phase 4

22316-47-8

2789

Zonisamide

Approved, Investigational

Phase 4

68291-97-4

5734

Clonazepam

Approved, Illicit

Phase 4

1622-61-3

2802

Rufinamide

Approved

Phase 4

106308-44-5

129228

Stiripentol

Approved

Phase 4

49763-96-4

Nitrazepam

Approved

Phase 4

146-22-5

4506

Ethosuximide

Approved

Phase 4

77-67-8

3291

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Alendronate

Approved

Phase 4

121268-17-5, 66376-36-1

2088

Lorazepam

Approved

Phase 4

846-49-1

3958

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Sulfamethoxazole

Approved

Phase 4

723-46-6

5329

Trimethoprim

Approved, Vet_approved

Phase 4

738-70-5

5578

Loratadine

Approved, Investigational

Phase 4

79794-75-5

3957

Metronidazole

Approved

Phase 4

443-48-1

4173

Ondansetron

Approved

Phase 4

99614-02-5

4595

Ertapenem

Approved, Investigational

Phase 4

153832-46-3

150610

Clarithromycin

Approved

Phase 4

81103-11-9

84029

Rifabutin

Approved, Investigational

Phase 4

72559-06-9

6323490 46783538

Ethambutol

Approved

Phase 4

74-55-5

3279 14052

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Fospropofol

Approved, Illicit, Investigational

Phase 4

258516-89-1, 258516-87-9

3038498

Levetiracetam

Approved

Phase 4

102767-28-2

441341

Pentetic acid

Approved

Phase 4

67-43-6

Edetic Acid

Approved, Vet_approved

Phase 4

60-00-4, 62-33-9

6049

chloroquine

Approved, Investigational, Vet_approved

Phase 4

54-05-7

2719

Budesonide

Approved

Phase 4

51333-22-3

63006 5281004

Nevirapine

Approved

Phase 4

129618-40-2

4463

Citalopram

Approved

Phase 4

59729-33-8

2771

Metoclopramide

Approved, Investigational

Phase 4

364-62-5

4168

Ketorolac

Approved

Phase 4

74103-06-3, 66635-83-4

3826

Phenol

Approved, Experimental

Phase 4

108-95-2

996

Oxacillin

Approved, Investigational

Phase 4

66-79-5

6196

Efavirenz

Approved, Investigational

Phase 4

154598-52-4

64139

carbamide peroxide

Approved

Phase 4

124-43-6

Daptomycin

Approved, Investigational

Phase 4

103060-53-3

16129629

Fentanyl

Approved, Illicit, Investigational, Vet_approved

Phase 4

437-38-7

3345

Aspirin

Approved, Vet_approved

Phase 4

50-78-2

2244

Insulin aspart

Approved

Phase 4

116094-23-6

16132418

Retapamulin

Approved

Phase 4

224452-66-8

6918462

Interventional clinical trials:

(show top 50) (show all 10000)

#	Name	Status	NCT ID	Phase	Drugs
1	Medication Induced Blood Pressure Reduction; Assessment of Cerebral Perfusion and Cognition in Hypertensive Elderly	Unknown status	NCT00966199	Phase 4	anti-hypertensive medication
2	Comparing the Effectiveness of 5 Artemisinin Combination Treatment Regimens in the Treatment of Uncomplicated Falciparum Malaria	Unknown status	NCT00902811	Phase 4	AM(FDC);AM(LT);AL;DP;AA(FDC)
3	Comparing Effectiveness of Post-operative Analgesia Between Patient Re-education and the Additional of a Basal Morphine Infusion to IV-PCA Morphine in Patients With Unsatisfactory Analgesia After Laparotomy	Unknown status	NCT02523846	Phase 4	morphine
4	Phase 4 Study of Balanced Propofol Sedation Versus Propofol Alone Sedation	Unknown status	NCT01321047	Phase 4	Propofol;BPS
5	Inhaled Salbutamol in Elective Caesarean Section	Unknown status	NCT01978418	Phase 4	salbutamol;Placebo
6	Atrial Fibrillation and Ischemic Events With Rivaroxaban in Patients With Stable Coronary Artery Disease Study (AFIRE Study)	Unknown status	NCT02642419	Phase 4	Rivaroxaban and single antiplatelet drug (aspirin, clopidogrel or prasugrel);Rivaroxaban
7	Effect of Dobutamine as Compared to Dopamine on Cerebral Oxygenation, Mean Arterial Pressure and Cerebral Hemodynamics in Term and Preterm Neonates With Arterial Hypotension	Unknown status	NCT01427686	Phase 4	Dobutamine;Dopamine
8	The Effect of a Circuit Resistance Training, Empagliflozin or "Vegeterranean Diet" on Physical and Metabolic Function in Elderly Subjects With Type 2 Diabetes: a Study Protocol for a Randomized Control Trial (CEV-65 Trial)	Unknown status	NCT03560375	Phase 4	Empagliflozin 10 MG
9	The Effect on an Ionic Silver Dressing in Head and Neck Patients With Malignant Fungating Wound	Unknown status	NCT00813631	Phase 4
10	Multicenter Study Evaluating the Efficacy of Dicopeg Junior in Comparison With Lactulose for the Treatment of Functional Constipation in Children Aged 6 Months to 6 Years. A Prospective, Randomized Study.	Unknown status	NCT03177434	Phase 4	polyethylene glycols (PEG) 3350;Lactulose Oral Product
11	Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects	Unknown status	NCT02123056	Phase 4	Metoprolol;Matching Placebo
12	A Prospective Evaluation of Capecitabine and Metabolite Pharmacokinetics in Elderly Breast and Colorectal Cancer Patients and Their Association With Toxicity and Molecular Markers of Enzyme Activity and Aging	Unknown status	NCT03465202	Phase 4	Capecitabine
13	Cognitive, Behavioral and Aging Effects of Pain Medication in Alcohol Users	Unknown status	NCT02945293	Phase 4
14	An Open-Label Pilot Study to Compare the Efficacy of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids	Unknown status	NCT01583478	Phase 4
15	AGe-adapted Benefits of Envarsus Versus Twice-daily Tacrolimus ImmunosuppressioN druGs After Kidney Transplantation (AGEING) - a Feasibility Study	Unknown status	NCT03005236	Phase 4	ENVARSUS;Standard twice daily tacrolimus
16	a Randomized Control Trial to Assess the Effect of Early vs Routine Iron Supplementation on Iron Store and Growth in Term Small for Gestational Age and Appropriate for Gestational Age Infants at 1 Year	Unknown status	NCT03171324	Phase 4	Iron Supplement
17	An Immunogenicity and Safety Study of Combined Adsorbed Tetanus, Low Dose Diphtheria and Acellular Pertussis Vaccine (Td5ap and Td1aP) Given as a School-leaving Booster to 14-15-year-old Children Primed With a Five Component Acellular Pertussis Vaccine at 3, 5 and 12 Months of Age, and a Booster Dose at 5½ Years of Age	Unknown status	NCT00870350	Phase 4
18	Rationalization of the Systemic Treatment of Age-related Macular Degeneration With Rheohemapheresis (RHF)	Unknown status	NCT01943396	Phase 4
19	A Phase IV, Open Label, Multi-Center, Study of Maintenance Intravitreous Injections of Macugen (Pegaptanib Sodium) Given Every 6 Weeks for 48 Weeks in Subjects With Subfoveal Neovascular Age-Related Macular Degeneration (AMD) Initially Treated With a Modality Resulting in Maculopathy Improvement	Unknown status	NCT00354445	Phase 4	pegaptanib sodium (Macugen)
20	A 7-month, Multicenter Study to Evaluate the Efficacy of Intravitreal Injections of Aflibercept (EYLEA) 2mg /0.05 ml as Secondary or Third Line Treatment for Neovascular Age-related Macular Degeneration (NVAMD).	Unknown status	NCT01918878	Phase 4	Aflibercept (EYLEA)
21	Comparison of Early Intervention of PDT Combination With Ranibizumab vs. Ranibizumab Monotherapy in Persistent PCV Patients With Initial Loading Dose	Unknown status	NCT02864472	Phase 4	Ranibizumab;ranibizumab PRN
22	Random, Open-label Multicenter, Phase IV Study Assessing the Safety and Efficacy of Two Regimens of Ranibizumab 0.5 mg in Chinese Patients With Neovascular AMD	Unknown status	NCT02810808	Phase 4	Ranibizumab
23	Two-week Retreatment Interval Study for Treated Age-related Macular Degeneration Refractory to Monthly Aflibercept	Unknown status	NCT03468296	Phase 4	Intravitreal Aflibercept Injection 2mg
24	Treat and Extend Therapy Using Intravitreal Aflibercept (IAI) for Previously Treated Patients Exiting the Wet Age-related Macular Degeneration Extension Study (0910)	Unknown status	NCT01961414	Phase 4	Aflibercept
25	Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results	Unknown status	NCT01657669	Phase 4	Intravitreal Aflibercept injection
26	On-label tReatment With Intravitreal Aflibercept Injection for Patients With Persistent Pigment Epithelial Detachments in Neovascular AMD.	Unknown status	NCT01670162	Phase 4	Aflibercept
27	Early Cognitive Function and Recovery in Elderly Patients After Laser Laryngeal Surgery: Desflurane-based vs Propofol-based Anesthesia	Unknown status	NCT03194074	Phase 4	Propofol;Desflurane
28	Influence on Incidence of Postoperative Delirium by Various Sedatives in Elderly Patients With Hip Fracture Under Lumbar Anesthesia: A Randomized, Control and Multi-center Trial	Unknown status	NCT03346226	Phase 4	Dexmedetomidine Hydrochloride;Propofol
29	Adverse Effects of Glucocorticoid Therapy on Bone in Childhood Crohn's Disease	Unknown status	NCT00609752	Phase 4	prednisolone
30	Safety Study of Enterovirus 71 Vaccine in Children Aged 6-35 Months Old	Unknown status	NCT02806531	Phase 4
31	A PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL OF THE SUPPLEMENTATION WITH KIOLIC® IN PATIENTS WITH DIAGNOSIS OF METABOLIC SYNDROME TO IMPROVE ENDOTHELIAL FUNCTION AND INFLAMMATORY STATE. "KYMES"	Unknown status	NCT01168700	Phase 4	aged garlic extract;Placebo
32	Oxidative Stress In Semen And Male Infertility	Unknown status	NCT03464656	Phase 4	Fairhaven Pro for men
33	Bivalirudin Plus Prasugrel vs Abciximab Plus Clopidogrel. Optimizing Ischemic Protection and Bleeding Risk in Patients With ST Elevation Myocardial Infarction Undergoing Primary Percutaneous Coronary Intervention	Unknown status	NCT01158846	Phase 4	prasugrel/bivalirudin;clopidogrel/abciximab
34	A Phase 4, Randomized, Open-Label Study to Assess Humoral and Intestinal Polio Immunity Following a Three-Dose Trivalent Inactivated Polio Vaccine Schedule Relative to Two Sequential Schedules of IPV/Bivalent Oral Polio Vaccines	Unknown status	NCT01841671	Phase 4
35	A Randomized Clinical Trial Comparing Standard and Invidualized Bowel Preparation for Colonoscopy	Unknown status	NCT03428724	Phase 4	Standard Preparation;Individualized Preparation
36	Influence of Albumin on the Development of Acute Renal Dysfunction Associated With Cardiac Surgery Under Extracorporeal Circulation	Unknown status	NCT03373318	Phase 4	Human albumin;Plasmalyte
37	Effect of Iron Supplementation on Psychomotor Development of Non-anemic Exclusively or Predominantly Breastfed Infants: Randomized, Double-blind, Placebo-controlled Trial.	Unknown status	NCT02242188	Phase 4	Iron
38	A Study of Efficacy and Safety of Telbivudine in Pregnancy for the Prevention of Perinatal Transmission of Hepatitis B Virus Infection	Unknown status	NCT00939068	Phase 4	Telbivudine
39	Outcome of Percutaneous Mechanical Thrombectomy to Treat Acute Deep Venous Thrombosis	Unknown status	NCT02959801	Phase 4
40	Randomized Control Trial of Dichloroacetate, Preoperative Carbohydrate Loading and Moderate Intensity Exercise on Muscle Insulin Resistance After Major Abdominal Surgery	Unknown status	NCT02469337	Phase 4	Dichloroacetate
41	ASSESSMENT OF GH-IGF1 AXIS AND TO STUDY RESPONSE TO GH THERAPY IN CHILDREN WITH CML IN REMISSION HAVING GH DEFICIENCY	Unknown status	NCT01901666	Phase 4	Growth Hormone
42	mRNA Expression as a Biomarker of Xolair (Omalizumab) Response	Unknown status	NCT01584687	Phase 4
43	The Acute Effects of Moderate Intensity Exercise and Caffeine Ingestion on Cognition in Non-Caffeine Consumers and Caffeine Consumers	Unknown status	NCT03400423	Phase 4	Caffeine
44	Applying Pharmacogenetics to Warfarin Dosing in Chinese Patients	Unknown status	NCT01610141	Phase 4
45	Breast Cancer Screening With MRI in Women Aged 50-75 Years With Extremely Dense Breast Tissue: the DENSE Trial	Unknown status	NCT01315015	Phase 4
46	The ED50 of DEX for Providing Sedation in Different Female Age Group	Unknown status	NCT02773017	Phase 4	Dexmedetomidine A;Dexmedetomidine B;Dexmedetomidine C
47	A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Titration Study of Aptensio XR® in Children Ages 4 to Under 6 Years Diagnosed With Attention Deficit-Hyperactivity Disorder (ADHD)	Unknown status	NCT02683265	Phase 4	Aptensio XR;Placebo
48	A 12-Month Open Label Safety Study of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR®) in Children Ages 4-5 Years Diagnosed With Attention-Deficit/Hyperactivity Disorder (ADHD)	Unknown status	NCT02677519	Phase 4	Aptensio XR
49	A Randomized Controlled Pilot Study Comparing the Efficacy of Topical Coal Tar to Topical Corticosteroids in Children Aged 1 to < 16 Years With Moderate-severe Atopic Dermatitis	Unknown status	NCT03461302	Phase 4	Topical coal tar;Topical corticosteroids
50	Pharmacogenetics in Anti-VEGF Treatment Non-responders Suffering Exudative Age-related Macular Degeneration (AMD): Genetic Correlations and Intraocular Cytokine Concentrations	Unknown status	NCT01213667	Phase 4	Ranibizumab

Search NIH Clinical Center for Aging

Sources

Genetic Tests for Aging

Sources

Anatomical Context for Aging

MalaCards organs/tissues related to Aging:

⁴⁰

Brain, Skin, Bone, Eye, Myeloid, Endothelial, Heart

Sources

Publications for Aging

Articles related to Aging:

(show top 50) (show all 30018)

#	Title	Authors	PMID	Year
1	Short telomeres are sufficient to cause the degenerative defects associated with aging. ⁵⁷	Armanios M...Greider CW	19944403	2009
2	Increased cell-to-cell variation in gene expression in ageing mouse heart. ⁵⁷	Bahar R...Vijg J	16791200	2006
3	Lamin A-dependent nuclear defects in human aging. ⁵⁷	Scaffidi P...Misteli T	16645051	2006
4	Gene regulation and DNA damage in the ageing human brain. ⁵⁷	Lu T...Yankner BA	15190254	2004
5	Strikingly higher frequency in centenarians and twins of mtDNA mutation causing remodeling of replication origin in leukocytes. ⁵⁷	Zhang J...Attardi G	12538859	2003
6	Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. ⁵⁷	Niemi AK...Majamaa K	12483296	2003
7	Genome dynamics in aging mice. ⁵⁷	Dolle ME...Vijg J	12421760	2002
8	Muscle-specific mutations accumulate with aging in critical human mtDNA control sites for replication. ⁵⁷	Wang Y...Attardi G	11274426	2001
9	Distinct spectra of somatic mutations accumulated with age in mouse heart and small intestine. ⁵⁷	Dolle ME...Vijg J	10900004	2000
10	Role of nuclear background and in vivo environment in variable segregation behavior of the aging-dependent T414G mutation at critical control site for human fibroblast mtDNA replication. ⁵⁷	Michikawa Y...Attardi G	15328912	1999
11	Aging-dependent large accumulation of point mutations in the human mtDNA control region for replication. ⁵⁷	Michikawa Y...Attardi G	10531063	1999
12	Mitochondrial genotype associated with longevity. ⁵⁷	Tanaka M...Yagi K	9449878	1998
13	Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. ⁵⁷	Corral-Debrinski M...Wallace DC	1303288	1992
14	Growing old: the most common mitochondrial disease of all? ⁵⁷	Harding AE	1303273	1992
15	Mosaicism for a specific somatic mitochondrial DNA mutation in adult human brain. ⁵⁷	Soong NW...Arnheim N	1303287	1992
16	Accumulation of deletions in human mitochondrial DNA during normal aging: analysis by quantitative PCR. ⁵⁷	Simonetti S...Schon EA	1463763	1992
17	Evidence for and against the causal involvement of mitochondrial DNA mutation in mammalian ageing. ⁵⁷	Bittles AH	1383763	1992
18	Mitochondrial genetics: a paradigm for aging and degenerative diseases? ⁵⁷	Wallace DC	1533953	1992
19	Icariin improves brain function decline in aging rats by enhancing neuronal autophagy through the AMPK/mTOR/ULK1 pathway. ⁶¹	Zheng J...Zhou Z	33556283	2021
20	Astaxanthin alleviates pathological brain aging through the upregulation of hippocampal synaptic proteins. ⁶¹	Liu N...Lai H	33269751	2021
21	Preventive electroacupuncture reduces cognitive deficits in a rat model of D-galactose-induced aging. ⁶¹	Yu CC...Kong LH	33229729	2021
22	Blood pressure as a predictor of everyday cognitive function in aging adults with and without fibromyalgia. ⁶¹	Kircher JA...Zettel-Watson L	32339069	2021
23	Volatile compounds sorption during the aging of Chinese Liquor (Baijiu) using Pottery Powder. ⁶¹	Li M...Xu Y	33310558	2021
24	Corrigendum to "The correlation of IRE1α oxidation with Nox4 activation in aging-associated vascular dysfunction" [Redox Biology 37 (2020) 101727]. ⁶¹	Lee HY...Chae HJ	33579668	2021
25	Effect of Jiajian Guishen Formula on the senescence-associated heterochromatic foci in mouse ovaria after induction of premature ovarian aging by the endocrine-disrupting agent 4-vinylcyclohexene diepoxide. ⁶¹	Su X...Shi Y	33358858	2021
26	In-vivo diffusion MRI protocol optimization for the chimpanzee brain and examination of aging effects on the primate optic nerve at 3T. ⁶¹	Zhang X...Li L	33359631	2021
27	Gratitude as a Mediator of the Effects of Savoring on Positive Adjustment to Aging. ⁶¹	Bryant FB...Smith JL	32370635	2021
28	Validation of a mass spectrometry method to identify and quantify ellagitannins in oak wood and cognac during aging in oak barrels. ⁶¹	Gadrat M...Chira K	33069531	2021
29	Effect of air-abrasion at pre- and/or post-sintered stage and hydrothermal aging on surface roughness, phase transformation, and flexural strength of multilayered monolithic zirconia. ⁶¹	Yilmaz AD...Okutan Y	33236475	2021
30	Seasonal variation of dicarboxylic acids in PM2.5 in Beijing: Implications for the formation and aging processes of secondary organic aerosols. ⁶¹	Yu Q...Ahmad M	33131838	2021
31	Analysis of aging type- and aging time-related changes in the polar fraction of metabolome of beef by 1H NMR spectroscopy. ⁶¹	Bischof G...Gibis M	33092915	2021
32	Oxygen consumption rate of lees during sparkling wine (Cava) aging; influence of the aging time. ⁶¹	Pons-Mercade P...Zamora F	33051100	2021
33	Is There Any Evidence of Premature, Accentuated and Accelerated Aging Effects on Neurocognition in People Living with HIV? A Systematic Review. ⁶¹	Aung HL...Cysique LA	33025390	2021
34	Effects of a 12-Week Cycling Intervention on Successful Aging Measures in Mid-Aged Adults. ⁶¹	Geard D...Reaburn P	32097099	2021
35	Biological aspects of aging that influence response to anticancer treatments. ⁶¹	Crimmin J...Battisti NML	33399393	2021
36	Aerobic exercise training decreases cognitive impairment caused by demyelination by regulating ROCK signaling pathway in aging mice. ⁶¹	Bao C...Li H	33358939	2021
37	Interactions of iron-based nanoparticles with soil dissolved organic matter: adsorption, aging, and effects on hexavalent chromium removal. ⁶¹	Hui C...Jiang H	33307452	2021
38	Risk- and protective factors for memory plasticity in aging. ⁶¹	Brathen ACS...Walhovd KB	32098566	2021
39	Probing menstrual bloodstain aging with fluorescence spectroscopy. ⁶¹	Wojtowicz A...Lednev IK	33279406	2021
40	Reservoir optimized plunger lift technology reduces hydrocarbon emissions from aging gas wells. ⁶¹	Hildenbrand ZL...Schug KA	33208255	2021
41	Proteodynamics and aging of eukaryotic cells. ⁶¹	Witkowski JM...Fulop T	33421431	2021
42	Diabetes multimorbidity combinations and disability in the Mexican Health and Aging Study, 2012-2015. ⁶¹	McClellan SP...Garcia-Pena C	33186887	2021
43	Physiological and pathological functions of TMEM106B: a gene associated with brain aging and multiple brain disorders. ⁶¹	Feng T...Hu F	33386471	2021
44	Testing a Model of Successful Aging on Masters Athletes and Non-Sporting Adults. ⁶¹	Geard D...Reaburn PRJ	32027570	2021
45	Human anterior pituitary's ACTH cells during the aging process: immunohistochemic and morphometric study. ⁶¹	Pavlovic M...Cukuranovic-Kokoris J	33098535	2021
46	Editorial for "Cardiac MRI Reveals Late Diastolic Changes in Left Ventricular Relaxation Patterns During Healthy Aging". ⁶¹	Ibrahim EH	33219621	2021
47	Critical Speed throughout Aging: Insight into the World Masters Championships. ⁶¹	Gifford JR...Collins J	33560767	2021
48	Integration of lncRNA and mRNA profiles to reveal the protective effects of Codonopsis pilosula extract on the gastrointestinal tract of mice subjected to D‑galactose‑induced aging. ⁶¹	Meng J...Wang J	33448313	2021
49	Accelerated aging: A marker for social factors resulting in cardiovascular events? ⁶¹	Forrester SN...Kiefe CI	33532540	2021
50	Effect of enological treatments on phenolic and sensory characteristics of red wine during aging: Micro-oxygenation, sulfur dioxide, iron with copper and gelatin fining. ⁶¹	Curko N...Teissedre PL	32871302	2021

Sources

Genes for Aging

Genes related to Aging (0 elite genes):

(show all 32)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	BCYRN1	Brain Cytoplasmic RNA 1	RNA Gene	157.03	Experimental evidence: Expression ³⁸ GeneCards inferred via : Publications (show sections)	17553964
2	KCNQ1DN	KCNQ1 Downstream Neighbor	RNA Gene	156.82	Experimental evidence: Epigenetics ³⁸ GeneCards inferred via : Publications (show sections)	22067257
3	PDGFRB	Platelet Derived Growth Factor Receptor Beta	Protein Coding	35.92	GeneCards inferred via : Disorders Publications Functions Variants (show sections)
4	LMNA	Lamin A/C	Protein Coding	34.95	GeneCards inferred via : Disorders Publications Functions Expressions (show sections)
5	NAMPT	Nicotinamide Phosphoribosyltransferase	Protein Coding	33.43	GeneCards inferred via : Publications Summaries Pathways & Interactions Functions (show sections)
6	SIRT3	Sirtuin 3	Protein Coding	33.43	GeneCards inferred via : Publications Summaries Pathways & Interactions Functions (show sections)
7	SIRT1	Sirtuin 1	Protein Coding	26.03	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
8	WRN	WRN RecQ Like Helicase	Protein Coding	25.75	GeneCards inferred via : Publications Summaries Functions (show sections)
9	SOD2	Superoxide Dismutase 2	Protein Coding	25.49	GeneCards inferred via : Publications Summaries Functions (show sections)
10	PARP1	Poly(ADP-Ribose) Polymerase 1	Protein Coding	24.4	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
11	FOXO3	Forkhead Box O3	Protein Coding	24.21	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
12	REST	RE1 Silencing Transcription Factor	Protein Coding	24.1	GeneCards inferred via : Publications Functions localization (show sections)
13	SIRT6	Sirtuin 6	Protein Coding	23.98	GeneCards inferred via : Publications Summaries Functions (show sections)
14	FOXO1	Forkhead Box O1	Protein Coding	23.96	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
15	PPARG	Peroxisome Proliferator Activated Receptor Gamma	Protein Coding	23.96	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
16	GDF11	Growth Differentiation Factor 11	Protein Coding	23.84	GeneCards inferred via : Publications Summaries Functions (show sections)
17	TP63	Tumor Protein P63	Protein Coding	23.73	GeneCards inferred via : Publications Summaries Functions (show sections)
18	RGN	Regucalcin	Protein Coding	23.7	GeneCards inferred via : Publications Summaries Functions (show sections)
19	HIF1A	Hypoxia Inducible Factor 1 Subunit Alpha	Protein Coding	23.65	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
20	NFKB1	Nuclear Factor Kappa B Subunit 1	Protein Coding	23.65	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
21	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	23.51	GeneCards inferred via : Publications Gene name Functions (show sections)
22	DAO	D-Amino Acid Oxidase	Protein Coding	23.35	GeneCards inferred via : Publications Summaries Functions (show sections)
23	NR2C2	Nuclear Receptor Subfamily 2 Group C Member 2	Protein Coding	23.21	GeneCards inferred via : Publications Summaries Functions (show sections)
24	TFAM	Transcription Factor A, Mitochondrial	Protein Coding	23.19	GeneCards inferred via : Publications Pathways & Interactions Functions (show sections)
25	VIM	Vimentin	Protein Coding	23.01	GeneCards inferred via : Publications Functions Variants (show sections)
26	MBP	Myelin Basic Protein	Protein Coding	21.86	GeneCards inferred via : Publications Proteins Functions (show sections)
27	APOE	Apolipoprotein E	Protein Coding	17.91	GeneCards inferred via : Publications Functions (show sections)
28	IGF1	Insulin Like Growth Factor 1	Protein Coding	17.03	GeneCards inferred via : Publications Functions (show sections)
29	KL	Klotho	Protein Coding	16.93	GeneCards inferred via : Publications Functions (show sections)
30	CAT	Catalase	Protein Coding	16.62	GeneCards inferred via : Publications Functions (show sections)
31	APP	Amyloid Beta Precursor Protein	Protein Coding	16.62	GeneCards inferred via : Publications Functions (show sections)
32	ACHE	Acetylcholinesterase (Cartwright Blood Group)	Protein Coding	16.41	GeneCards inferred via : Publications Functions (show sections)

Sources

Variations for Aging

Sources

Expression for Aging

Search GEO for disease gene expression data for Aging.

Sources

Pathways for Aging

Pathways related to Aging according to GeneCards Suite gene sharing:

(show all 26)

#	Super pathways	Score	Top Affiliating Genes
1	Endometrial cancer ³⁶ Show member pathways Acute myeloid leukemia ³⁶ Binding of TCF/LEF-CTNNB1 to target gene promoters ⁶⁵ Chronic myeloid leukemia ³⁶ Colorectal cancer ³⁶ Pancreatic cancer ³⁶ Prostate cancer ³⁶ Signal transduction PTEN pathway ²³ Thyroid cancer ³⁶	12.75	PPARG PDGFRB NFKB1 FOXO3 FOXO1
2	Pathways in cancer ³⁶	12.72	PPARG PDGFRB NFKB1 HIF1A FOXO1
3	4-1BB Pathway ⁶³ Show member pathways CD27 Pathway ⁶³ CD40 Signaling ⁶³ CMV and MAPK Pathways ⁶³ NF-KappaB Activation by EBV ⁶³ NF-kappaB Activation by Viruses ⁶³ PKR Pathway ⁶³ SUMO Pathway ⁶³ TNFR2 Pathway ⁶³	12.56	SIRT6 SIRT3 SIRT1 PDGFRB NFKB1
4	ErbB signaling pathway ³⁶ ¹ Show member pathways EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ³⁶ Renal cell carcinoma ³⁶ TCA Cycle Nutrient Utilization and Invasiveness of Ovarian Cancer ¹	12.51	PDGFRB NFKB1 HIF1A FOXO3 FOXO1
5	MicroRNAs in cancer ³⁶	12.41	TP63 SIRT1 PDGFRB NFKB1
6	Glucose / Energy Metabolism ⁴	12.38	SOD2 SIRT3 SIRT1 PPARG NAMPT
7	AMP-activated Protein Kinase (AMPK) Signaling ¹ Show member pathways AMPK signaling pathway ³⁶ AMPK Signaling Pathway ⁶⁶	12.37	SIRT1 PPARG FOXO3 FOXO1
8	p53 Signaling ⁶³ Show member pathways P53 Pathway ⁶⁶	12.15	SIRT6 SIRT3 SIRT1 HIF1A
9	NAD metabolism ²³ Show member pathways NAD salvage ¹ NAD+ biosynthetic pathways ¹ NAD+ metabolism ¹ NADH repair ¹ Nicotinamide salvaging ⁶⁵ Nicotinate and nicotinamide metabolism ³⁶ Nicotinate metabolism ⁶⁵	12.08	SIRT6 SIRT3 SIRT1 PARP1 NAMPT
10	Cellular senescence (KEGG) ³⁶	12.03	SIRT1 NFKB1 FOXO3 FOXO1
11	FoxO signaling pathway ³⁶ Show member pathways PLK2 and PLK4 events ¹ Polo-like kinase signaling events in the cell cycle ¹	11.96	SOD2 SIRT1 FOXO3 FOXO1
12	Adipogenesis ¹	11.89	PPARG NAMPT LMNA HIF1A FOXO1
13	DNA Damage Response (only ATM dependent) ¹	11.86	SOD2 NFKB1 FOXO3
14	Interleukin-4 and 13 signaling ⁶⁵	11.86	HIF1A FOXO3 FOXO1
15	TGF-beta Signaling Pathways ⁶⁴	11.76	PPARG NFKB1 FOXO3 FOXO1
16	MAPK Signaling: Oxidative Stress Pathway ⁶⁴	11.67	SIRT1 FOXO3 FOXO1
17	Longevity regulating pathway ³⁶ Show member pathways Longevity regulating pathway - multiple species ³⁶	11.61	SOD2 SIRT1 PPARG NFKB1 FOXO3 FOXO1
18	Central carbon metabolism in cancer ³⁶	11.6	SIRT6 SIRT3 PDGFRB HIF1A
19	AGE/RAGE pathway ¹	11.58	NFKB1 HIF1A FOXO1
20	Neurodegenerative Diseases ⁶⁵ Show member pathways Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimers disease models ⁶⁵	11.39	SOD2 LMNA FOXO3
21	FoxO family signaling ¹	11.39	SOD2 SIRT1 FOXO3 FOXO1
22	Signaling events mediated by HDAC Class I ¹	11.37	SIRT6 SIRT3 SIRT1 PPARG NFKB1
23	Melatonin metabolism and effects ¹	11.25	SIRT1 NFKB1 FOXO1
24	Signaling events mediated by HDAC Class III ¹	11.21	SIRT3 SIRT1 FOXO3 FOXO1
25	DNA damage_NHEJ mechanisms of DSBs repair ²³	10.94	WRN SIRT6 SIRT3 SIRT1
26	NAD metabolism, sirtuins and aging ¹	10.32	SIRT3 SIRT1 PPARG PARP1 NFKB1 NAMPT

Sources

GO Terms for Aging

Cellular components related to Aging according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	cytoplasm	GO:0005737	10.13	WRN TP63 SOD2 SIRT6 SIRT1 RGN
2	mitochondrion	GO:0005739	9.92	TP63 SOD2 SIRT3 SIRT1 PARP1 NFKB1
3	chromatin	GO:0000785	9.91	TP63 SIRT1 PPARG NFKB1 HIF1A FOXO3
4	nucleus	GO:0005634	9.86	WRN TP63 SIRT6 SIRT3 SIRT1 RGN
5	protein-containing complex	GO:0032991	9.7	TP63 SIRT3 SIRT1 PARP1 HIF1A GDF11
6	nucleoplasm	GO:0005654	9.47	WRN TP63 SIRT6 SIRT3 SIRT1 REST

Biological processes related to Aging according to GeneCards Suite gene sharing:

(show all 37)

#	Name	GO ID	Score	Top Affiliating Genes
1	regulation of transcription by RNA polymerase II	GO:0006357	10.22	TP63 SOD2 REST PPARG NFKB1 HIF1A
2	regulation of transcription, DNA-templated	GO:0006355	10.21	TP63 REST PPARG NFKB1 HIF1A FOXO3
3	cellular response to DNA damage stimulus	GO:0006974	10.04	WRN TP63 SIRT1 PARP1 FOXO1
4	apoptotic process	GO:0006915	10.04	TP63 SIRT1 PARP1 NFKB1 FOXO3 FOXO1
5	negative regulation of cell proliferation	GO:0008285	10.03	SOD2 REST PPARG LMNA GDF11
6	negative regulation of transcription, DNA-templated	GO:0045892	10.02	TP63 SIRT1 REST PPARG NFKB1 FOXO1
7	positive regulation of transcription, DNA-templated	GO:0045893	9.98	TP63 REST PPARG NFKB1 HIF1A FOXO3
8	negative regulation of gene expression	GO:0010629	9.97	SIRT1 REST NFKB1 HIF1A
9	negative regulation of transcription by RNA polymerase II	GO:0000122	9.91	TP63 SIRT6 SIRT1 REST PPARG PARP1
10	positive regulation of apoptotic process	GO:0043065	9.88	SIRT1 REST PPARG PDGFRB FOXO3 FOXO1
11	negative regulation of apoptotic process	GO:0043066	9.87	SOD2 SIRT1 RGN PDGFRB NFKB1 HIF1A
12	cellular response to insulin stimulus	GO:0032869	9.83	PPARG PARP1 FOXO1
13	cellular response to starvation	GO:0009267	9.81	WRN SIRT1 FOXO1
14	cellular response to oxidative stress	GO:0034599	9.78	SOD2 PARP1 FOXO3 FOXO1
15	positive regulation of autophagy	GO:0010508	9.77	HIF1A FOXO3 FOXO1
16	response to hydrogen peroxide	GO:0042542	9.75	SOD2 SIRT1 PDGFRB
17	positive regulation of pri-miRNA transcription by RNA polymerase II	GO:1902895	9.71	PPARG HIF1A FOXO3
18	cell aging	GO:0007569	9.7	WRN TP63 SIRT1
19	response to lipid	GO:0033993	9.67	PPARG PDGFRB
20	multicellular organism aging	GO:0010259	9.67	WRN TP63
21	negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway	GO:1902176	9.65	SOD2 SIRT1
22	white fat cell differentiation	GO:0050872	9.65	SIRT1 PPARG
23	DNA synthesis involved in DNA repair	GO:0000731	9.65	WRN SIRT1
24	positive regulation of transcription by RNA polymerase II	GO:0045944	9.65	TP63 SIRT1 REST PPARG PARP1 NFKB1
25	positive regulation of vascular associated smooth muscle cell apoptotic process	GO:1905461	9.64	SOD2 PPARG
26	negative regulation of cellular senescence	GO:2000773	9.63	TP63 SIRT1 NAMPT
27	negative regulation of cardiac muscle hypertrophy in response to stress	GO:1903243	9.62	LMNA FOXO1
28	retina vasculature development in camera-type eye	GO:0061298	9.61	PDGFRB HIF1A
29	peptidyl-lysine deacetylation	GO:0034983	9.61	SIRT3 SIRT1
30	oxygen homeostasis	GO:0032364	9.6	SOD2 HIF1A
31	cellular response to hyperoxia	GO:0071455	9.58	PPARG FOXO1
32	positive regulation of superoxide dismutase activity	GO:1901671	9.56	SIRT3 RGN
33	protein deacetylation	GO:0006476	9.54	SIRT6 SIRT3 SIRT1
34	histone H3-K9 deacetylation	GO:1990619	9.51	SIRT6 SIRT1
35	histone H3-K9 modification	GO:0061647	9.49	SIRT6 SIRT1
36	protein ADP-ribosylation	GO:0006471	9.46	SIRT6 SIRT3 SIRT1 PARP1
37	aging	GO:0007568	9.17	WRN TP63 SOD2 SIRT3 RGN PDGFRB

Molecular functions related to Aging according to GeneCards Suite gene sharing:

(show all 20)

#	Name	GO ID	Score	Top Affiliating Genes
1	DNA binding	GO:0003677	10.22	WRN TP63 SOD2 REST PPARG PARP1
2	identical protein binding	GO:0042802	10.14	TP63 SOD2 SIRT1 PPARG PARP1 NFKB1
3	DNA-binding transcription factor activity, RNA polymerase II-specific	GO:0000981	10.11	TP63 REST PPARG NFKB1 HIF1A FOXO3
4	RNA polymerase II proximal promoter sequence-specific DNA binding	GO:0000978	10.11	TP63 SIRT1 REST PPARG NFKB1 HIF1A
5	DNA-binding transcription factor activity	GO:0003700	9.98	TP63 REST PPARG NFKB1 HIF1A FOXO3
6	DNA-binding transcription activator activity, RNA polymerase II-specific	GO:0001228	9.96	TP63 NFKB1 HIF1A FOXO3 FOXO1
7	chromatin binding	GO:0003682	9.93	WRN TP63 REST PPARG NFKB1 FOXO1
8	DNA-binding transcription repressor activity, RNA polymerase II-specific	GO:0001227	9.89	REST PPARG NFKB1 FOXO3
9	transcription regulatory region sequence-specific DNA binding	GO:0000976	9.88	TP63 REST PPARG NFKB1 FOXO3
10	transcription factor binding	GO:0008134	9.85	SIRT1 REST PPARG PARP1 NFKB1 HIF1A
11	enzyme binding	GO:0019899	9.8	SOD2 SIRT3 SIRT1 PPARG PDGFRB PARP1
12	p53 binding	GO:0002039	9.72	TP63 SIRT1 HIF1A
13	deacetylase activity	GO:0019213	9.58	SIRT6 SIRT1
14	protein deacetylase activity	GO:0033558	9.58	SIRT6 SIRT1
15	NAD+ binding	GO:0070403	9.58	SIRT6 SIRT3 SIRT1
16	NAD-dependent protein deacetylase activity	GO:0034979	9.5	SIRT6 SIRT3 SIRT1
17	NAD-dependent histone deacetylase activity (H3-K9 specific)	GO:0046969	9.49	SIRT6 SIRT1
18	NAD+ ADP-ribosyltransferase activity	GO:0003950	9.46	SIRT6 SIRT3 SIRT1 PARP1
19	sequence-specific DNA binding	GO:0043565	9.23	TP63 SIRT3 REST PPARG NFKB1 HIF1A
20	NAD-dependent histone deacetylase activity	GO:0017136	9.13	SIRT6 SIRT3 SIRT1

Sources

Sources for Aging

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ EFO

¹⁸ ExPASy

¹⁹ FMA

²⁰ GARD

²¹ GeneAnalytics

²² GeneCards

²³ GeneGo (Thomson Reuters)

²⁴ GeneHancer via GeneCards

²⁵ GeneReviews

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HMDB

³¹ HPO

³² ICD10

³³ ICD10 via Orphanet

³⁴ ICD9CM

³⁵ IUPHAR

³⁶ KEGG

³⁷ LifeMap

³⁸ LncRNADisease

³⁹ LOVD

⁴⁰ MalaCards

⁴¹ MedGen

⁴² MedlinePlus

⁴³ MedlinePlus Genetics

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NINDS

⁵⁴ Novoseek

⁵⁵ Novus Biologicals

⁵⁶ OMIM via Orphanet

⁵⁷ OMIM® (Updated 05-Mar-2021)

⁵⁸ Orphanet

⁵⁹ PathCards

⁶⁰ PharmGKB

⁶¹ PubMed

⁶² PubMed Health

⁶³ QIAGEN

⁶⁴ R&D Systems

⁶⁵ Reactome

⁶⁶ Sino Biological

⁶⁷ SNOMED-CT

⁶⁸ SNOMED-CT via HPO

⁶⁹ TGDB

⁷⁰ Tocris

⁷¹ UMLS

⁷² UMLS via Orphanet

⁷³ UniProtKB/Swiss-Prot

⁷⁴ Wikipedia

Aging (AGING)

Aliases & Classifications for Aging

MalaCards integrated aliases for Aging:

External Ids:

Summaries for Aging

Related Diseases for Aging

Diseases related to Aging via text searches within MalaCards or GeneCards Suite gene sharing:

Graphical network of the top 20 diseases related to Aging:

Symptoms & Phenotypes for Aging

Clinical features from OMIM®:

GenomeRNAi Phenotypes related to Aging according to GeneCards Suite gene sharing:

MGI Mouse Phenotypes related to Aging:

Drugs & Therapeutics for Aging

Drugs for Aging (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

Interventional clinical trials:

Genetic Tests for Aging

Anatomical Context for Aging

MalaCards organs/tissues related to Aging:

Publications for Aging

Articles related to Aging:

Genes for Aging

Genes related to Aging (0 elite genes):

Variations for Aging

Expression for Aging

Pathways for Aging

Pathways related to Aging according to GeneCards Suite gene sharing:

GO Terms for Aging

Cellular components related to Aging according to GeneCards Suite gene sharing:

Biological processes related to Aging according to GeneCards Suite gene sharing:

Molecular functions related to Aging according to GeneCards Suite gene sharing:

Sources for Aging